Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report

Abstract

Management of ticagrelor-associated bleeding is challenging, especially in neurosurgery. Platelet transfusion is inefficient and no antidote is currently available. We report here the first case of recombinant activated factor VII (rFVIIa) use to bypass ticagrelor-induced platelet inhibition. A woman treated with ticagrelor and requiring emergent neurosurgery for an intracranial hematoma received preoperative high-dose platelet transfusion and 60 μg/kg rFVIIa. Laboratory monitoring demonstrated that platelet transfusion failed to reverse ticagrelor-induced platelet inhibition while rFVIIa improved hemostasis by shortening the thromboelastometric clotting time. Neurosurgery occurred without any bleeding event but the patient presented with a postoperative pulmonary embolism. In conclusion, rFVIIa may decrease ticagrelor-induced bleeding risk but careful assessment of the benefit-risk balance is warranted before using rFVIIa to reverse ticagrelor effects.

Keywords

antithrombotic - platelet transfusion - recombinant activated factor VII - reversal - ticagrelor

• References

• 1 EMEA. Ticagrelor, product information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/001241/WC500100494.pdf . Accessed January 2018
• 2 Teng R, Mitchell PD, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Ther 2014; 39 (02) 186-191
• 3 O'Connor SA, Amour J, Mercadier A. , et al; ACTION Study Group. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv 2015; 8 (11) e002786
• 4 Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10 (08) 1478-1485
• 5 Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. Anesth Analg 2011; 113 (04) 703-710
• 6 Calmette L, Martin AC, Le Bonniec B. , et al. Ticagrelor reversal: in vitro assessment of four haemostatic agents. J Clin Pathol 2017; 70 (09) 733-739
• 7 Pehrsson S, Hansson K, Nelander K, Nylander S. Boosting the coagulation restores haemostasis in ticagrelor-treated mice. Blood Coagul Fibrinolysis 2016; 27 (08) 913-919
• 8 Frontera JA, Lewin III JJ, Rabinstein AA. , et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24 (01) 6-46
• 9 Recommandation de Bonne Pratique. Transfusion de plaquettes: produits, indications. Available at: https://www.has-sante.fr/portail/upload/docs/application/pdf/2015-11/recommandations_-_transfusion_de_plaquettes.pdf . Accessed July 2018
• 10 Lavigne-Lissalde G, Aya AG, Mercier FJ. , et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost 2015; 13 (04) 520-529
• 11 Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thromb Haemost 2016; 116 (04) 638-650
• 12 Lang T, Bauters A, Braun SL. , et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16 (04) 301-310
• 13 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
• 14 Gurbel PA, Bliden KP, Butler K. , et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25) 2577-2585
• 15 Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015; 372 (02) 196-197
• 16 Maillard J, Cartier Faessler V, Fontana P, Bonhomme F. Lack of effect of platelet transfusions and desmopressin on intracranial bleeding in a patient receiving ticagrelor. A A Case Rep 2015; 4 (12) 169-171
• 17 Martin AC, Berndt C, Calmette L. , et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 2016; 33 (05) 361-367
• 18 Filaire L, Pham DT, d'Ostrevy N, Tran HT, Camilleri L, Azarnoush K. Inefficacy of platelet transfusion in a heart transplant patient under continuous ticagrelor. J Cardiothorac Vasc Anesth 2017; 31 (05) 1776-1778
• 19 Willeman T, Marlu R, Böhle H. , et al. Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed. Clin Toxicol (Phila) 2018; (Epub ahead of print); DOI: 10.1080/15563650.2018.1480026.
• 20 Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108 (05) 1447-1452
• 21 Godier A, Greinacher A, Faraoni D, Levy JH, Samama CM. Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (01) 170-174